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Summary 
B7/BB1 is a membrane differentiation antigen expressed on activated B cells, macrophages, and 
dendritic cells that binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. 
Interaction between CD28 and B7 results in potent costimulation of T cell activation initiated 
via the CD3/T  cell receptor complex.  We now report  that  B7 is also expressed on activated 
human peripheral blood T  cells,  CD4 T  cell clones, CD8 T  cell clones, and natural  killer cell 
clones. B7 appears relatively late after T cell activation, can be detected on both CD4 and CD8 
T  cell subsets, and is present on antigen-specific,  major histocompatibility complex-restricted 
CD4  and  CD8  T  cell  clones.  Expression  of B7  on  activated  T  cells  was  confirmed  by 
immunoprecipitation  from 12SI-labded activated T  cells and by detection of B7 transcripts.  A 
B7 ~ CD4 + T  cell clone was able to stimulate a primary allogeneic mixed lymphocyte response 
using small, resting peripheral blood T cells as responders. The alloantigen-induced proliferative 
response and cytokine production was partially inhibited by anti-B7 monoclonal antibody. Since 
activated T cells can coexpress both CD28 and its counter-receptor, B7, this suggests that activated 
T  cells  may be capable of autocrine costimulation  via the CD28  activation pathway. 
B 
7/BB1 is a cell surface antigen expressed on activated B 
cells, macrophages, and dendritic cells (1-3). While B7 
is constitutively expressed on dendritic cells  (3),  it is only 
present in substantial levels after activation of B cells and mono- 
cytes. This antigen is upregulated on B cells after infection 
with EBV (2) or after stimulation with anti-Ig (1) or anti- 
HLA-DR (4). Levels of B7 expression induced by anti-Ig can 
be increased by Ib2 or II-4 (5). IFN-3, is capable of inducing 
B7 expression on monocytes (6). B7 is a 50-70-kD glycopro- 
tein and is encoded by a gene that  is a member of the Ig 
superfamily (7). 
B7  binds  to  CD28  (8),  a  cell  surface  disulfide-linked 
homodimer  that  is constitutively expressed on thymocytes 
and the majority of T lymphocytes (9, 10). The interaction 
between CD28 and B7 results in augmentation of T cell ac- 
tivation  initiated  through  the  TCR  (4,  8,  11-13).  CD28 
costimulation of T cells results in induction of II.-2 transcrip- 
tion (14) and stabilization  of cytokine mRNA (15),  and is 
resistant to inhibition by r  A (16). In a prior study, 
it was observed that  HTLV-I-transformed T  cells may also 
express B7 (17),  suggesting the possibility that T  cells may 
coexpress both CD28 and its counter-receptor under certain 
i The first two authors contributed equally to these studies. 
circumstances.  Herein, we have investigated whether normal, 
nontransformed T cells are capable of expressing functional 
B7 antigens. 
Materials and Methods 
Preparation of Lymphocytes and Cell Culture.  Human peripheral 
blood was obtained from the Stanford Blood Center (Palo Alto, 
CA). PBMC were isolated by Ficoll/Hypaque gradient centrifuga- 
tion. Small, resting T cells were isolated using Percoll density gra- 
dients after removal of B cells and monocytes by plastic and nylon 
wool adherence, as previously described (13). Cells were cultured 
in  Yssel's modified Iscove's medium  (18) or RPMI  1640 (JRH 
Biosdences, Lexena, KS) containing 10% FCS (JKI-I Biosdences), 
t-glutamine, and antibiotics. Human rlL-2 was generously provided 
by Dr. Gerard Zurawski (DNAX). A series of CD4 § T cell dones, 
CD8 + T  cell clones, and NK cell clones was established from 
normal PBL. Clones were cultured in medium supplemented with 
rlI.-2 and were restimulated using PHA, irradiated PBMC, and ir- 
radiated EBV B lymphoblastoid ceils, as described previously (18). 
The properties of the antigen-spedfic T cell dones have been de- 
scribed previously (19-22). 
mAbs, Immunofluorescencg and Flow Cytometry.  Methods ofim- 
munofluorescent staining, flow cytometry, and data analysis have 
been described  previously (23). Flow cytometry was performed using 
a FACScan  |  or FACStar Flus  |  (Becton Dickinson & Co., Moun- 
tain View, CA).  All mAbs were generously provided by Becton 
Dickinson & Co., unless otherwise noted. BB1 mAb (2) was the 
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WA). Anti-B7 mAbs L307 (IgG1) and L308 (IgM) were generated 
by immunizing  C3H/HeJ mice with BT-transfected g cells and 
fusing immune splenocytes with Sp2/0 myeloma cells, as described 
previously (24). 
Biochemistry.  Radioiodination, immunoprecipitation,  and elec- 
trophoresis were performed as previously described (25,.26).  Ra- 
dioactive proteins were detected using a Phosphorlmager  (Molec- 
ular Dynamics,  Inc., Sunnyvale, CA). 
Results and Discussion 
Expression of B7 on Activated T  Lymphocytes and T  Cell 
Clones.  Analysis of a series of human T cell clones indicated 
that the majority expressed B7 on the cell surface,  as deter- 
mined by immunofluorescence and flow cytometry. Expres- 
sion of B7 on T cell clones was not restricted to a particular 
subset since both CD3+CD4 + T  cell clones (14 of 16 ex- 
amined)  and  CD3+CD8 +  T  cell clones  (14  of 14  exam- 
ined)  were  found.  Moreover,  B7  was  also  present  on 
CD3-CD56 + NK cell clones (five of five examined),  but 
was  not  detected  on  freshly  isolated  PBL  NK  cells  (not 
shown). The levels of B7 varied between different clones and 
ranged from very high levels of expression to undetectable. 
Most of the  B7 +  T  cell clones examined  coexpressed the 
counter-receptor,  CD28,  whereas  all  B7 +  NK cell clones 
were CD28 negative.  Representative T  and NK cell clones 
are shown in Fig.  1.  Although  the antigenic  specificity of 
most of the T  cell clones surveyed in our panel was not de- 
termined,  B7 was detected on several well-characterized T 
cell clones of known specificity and function.  For example, 
HY-827 is a CD4 +, HLA-DR3-restricted T  cell clone that 
recognizes  a  peptide  of tetanus  toxoid  (19),  HY-06  is  a 
CD4 +,  HLA-DR3-restricted  T  cell clone that  recognizes 
mycobacterial  HSP-65  antigen  (20),  AG150  is  a  CD4 +, 
HLA-DR4-restricted T cell clone recognizing the DerpI house 
dust mite allergen (21), and CTL Q66.40 is a CD8 + , HLA- 
A2-restricted T cell clone reacting with an influenza peptide 
(22) (Fig.  1). The presence of B7 on T  cell clones was rela- 
tively stable over time, although differences in levels of ex- 
pression were observed. 
The presence of B7 on most T  cell clones prompted us 
to examine induction of this antigen on PBL T cells. Consis- 
tent with prior findings, B7 was not detected on freshly iso- 
lated PBL T cells (Fig.  2). PBMC were stimulated with im- 
mobilized anti-CD3,  and 100 IU/ml rib2 was added to the 
culture after 5 d. Cells were examined on days 1, 3, 5,  10, 
and 12 for induction of B7. Using these conditions, B7 ap- 
peared gradually on the T  cells over the course of culture, 
and maximal expression occurred after 10 d when >80% of 
T  cells coexpressed B7 (Fig.  2). The majority of both CD4 
and  CD8  T  cells  were B7 + .  Consistent  results  were  ob- 
tained using PBMC from three independent donors. The rel- 
atively late induction and the low levels of expression on some 
T  cell clones likely accounts for prior reports that activated 
T  cells  failed to express B7 (2,  17). 
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Figure  1.  Expression of B7 on T and NK cell clones. Representative 
CD4 + and CD8 + T cell clones and a CD3-,CD56 + NK cell done were 
stained with PE-conjugated anti-B7 mAb L307, PE-conjugated anti-CD28 
mAb L293, or PE-conjugated  IgG1 control mAb. Samples were analyzed 
by flow cytometry. The x-axis represents fluorescence (four-decade  log scale) 
and the y axis represents the relative cell number.  Histograms from cells 
stained with control mAb (nearest the y-axis) are superimposed over the 
histograms  of cells stained with anti-B7  or anti-CD28, as indicated. 
Biochemical Analysis ofT Cell-associated  B7 Antigen.  The 
presence orB7 on activated T cell populations and T cell clones 
was confirmed by immunofluorescent  staining using three 
different mAbs against B7 (i.e., BB1, L307, L308) (not shown). 
Specificity of the immunofluorescent staining was substan- 
tiated by biochemical verification (Fig.  3). A CD4 + T  clone 
(AW27-19) and a polyclonal population of anti-CD3 and rib 
2-activated PBL T  cells  were 12si labeled, detergent lysed, 
and B7 antigen was immunoprecipitated and analyzed by SDS- 
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Figure 2.  Induction of B7 on PBL T lymphocytes. Plastic tissue cul- 
ture flasks (Falcon Labware, Lincoln  Park, NJ) were coated with 10/~g]ml 
anti-CD3 (Leu-4) in PBS for I  h and then washed extensively. PBMC 
(106 cdls/ml) were activated by culture in anti-CD3-coated  tissue culture 
flasks. After 5 d, the media were supplemented with 100 IU/ml rIL-2, 
and culture was continued. Freshly isolated PBL T cells (.4) and day 10 
activated PBL T cells (B) were stained with PE-conjugated anti-B7- and 
FITC-conjugated anti-CD3 (Leu-4), anti-CD4 (Leu-3a), or anti-CDSce 
(Leu-2a), or with FITC- and PE-conjugated control Ig. Samples were ana- 
lyzed by flow cytometry. Data are displayed as contour plots of correlated 
FITC and PE fluorescence  (four-decade  log scales). Quadrant markers were 
positioned to include >98% of control Ig stained ceils in the lower left. 
PAGE. Similar to the molecular mass of B7 expressed on EBV- 
transformed B cell lines (1, 2), the B7 glycoprotein on acti- 
vated T cells was also *50-70 kD. Expression of B7 in NK 
and T  cell clones was further supported by detection of B7 
transcripts using reverse transcription and PCR. amplification 
(not shown). 
B7 + T  Cell Clones Stimulate a Primary Alloantigen  MLR. 
Prior studies have established that B7 costimulation is required 
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Figure 3.  Immunoprecipitation orB7. B7 § CD4 + T cell done AW27- 
19 (see Fig. 1) and a polyclonal population of PBL T cells activated with 
anti-CD3 and 100 IU/ml rlL-2 for 12 d were labeled with 12si, lysed in 
1% NP-40 lysis  buffer, and immunoprecipitated with formalin-fixed Staph- 
ylococcus aureus coated with rabbit anti-mouse Ig and control mouse Ig 
(C) or anti-B7 mAb L307 (25, 26). Antigens were eluted in sample buffer 
containing 10% 2-ME and were analyzed using 9% (/eft) or 10% (right) 
SDS-PAGE gels. 
for the ef~cient generation of a primary MLR directed against 
aUoantigen (13,  27).  mAbs against B7 partially inhibit an 
alloantigen-induced MLR  (3,  4),  and transfection of B7- 
negative B lymphoma cell lines with B7 cDNA substantially 
augments their ability to stimulate a primary T cell immune 
response (13, 27).  The detection of B7 on activated T  cells 
suggested that this may enable these T cells to act themselves 
as costimulators of a primary T  cell response. Since human 
activated T  cells express both MHC class II and class I in- 
tigens and B7, they might be expected to serve as stimulators 
of an allogeneic MLR. To examine this possibility, a CD4 + 
T  cell clone expressing B7 (Fig.  1, CD4-AW27-19) was ir- 
radiated and used as the stimulator in a primary MLK cul- 
ture  using  freshly isolated  small,  resting  PBL  T  cells  as 
responders. As shown in Table 1, a vigorous MLR response 
was observed using small, resting PBL responder T cells from 
three different donors. Both the alloantigen-induced prolifer- 
ative response, as well as the secretion of IFN-% were par- 
tially ('~30-50%) inhibited by the presence of anti-B7 mAb, 
similar to the level of inhibition observed with anti-CD4 or 
anti-HLA-DR mAbs (Table 1). These results are comparable 
to prior reports that anti-B7 is capable of partially inhibiting 
alloantigen MLR generated with EBV B lymphoblastoid cells 
as stimulators  (3,  4). 
Conclusions.  B7 is not restricted in expression to "con- 
ventional" APC since this glycoprotein is also present on most 
activated T  and NK cells.  The ability of B7 + activated T 
cell clones to stimulate a primary allogeneic MLR response 
substantiates the fact that expression of B7 is functionally 
competent. Prior studies have demonstrated that activated 
T  and NK cell clones possess the ability to present peptide 
847  Azuma et al.  Brief Definitive Report Table  1.  B7 §  T  Cell Clone AFV27-I9  Stimulates Primary Allaantigen-induced  Proliferative  and Cytokine  Responses 
Using  Small,  Resting  T  Cells as Responders 
[3H]TdR incorporation 
Small,  resting  Irradiated B7;  T 
T  responders  stimulators  mAb added  Exp.  1  Exp.  2  Exp.  3 
cl)rrl  x  10 -3 
+  +  Control  20,3  (~-)*  15.3  (-)  14.7  (-) 
+  +  c~B7  9.8  (51.7)  9.5  (37.9)  6.3  (57.3) 
+  +  otCD4  8.5  (58.1)  7.5  (49.6)  7.7  (45.9) 
+  +  ctHLA-DR  5.5  (72,4)  7.7  (50.9)  7.4  (49.8) 
+  +  aCD4  +  HLA-DR  2.5  (87.7)  7.3  (52.3)  2.6  (81.6) 
+  -  None  1.0  2.3  1.0 
-  +  None  1.5  1.6  2.2 
IFN-3, production 
Exp.  1  Exp.  2  Exp.  3 
pg/ml 
+  +  Control  5,650  (-)*  6,685  (-)  3,600  (-) 
+  +  c~B7  2,840  (48.2)  4,750  (28.9)  1,580  (56.1) 
+  +  c~CD4  2,505  (55.6)  4.200  (37.1)  2,125  (40.9) 
+  +  txHLA-DR  1,520  (73.1)  5,915  (11.5)  1,600  (55.5) 
+  +  txCD4  +  HLA-DR  975  (82.7)  500  (92.5)  870  (75.8) 
+  -  None  <50  <50  <50 
-  +  None  <50  <50  <50 
Freshly isolated small, resting PBL T cells (2  x  10  s calls/well) from three different blood donors (Exps. 1-3) were cocultured with irradiated (4,000 
rad) B7 + T cell done AW27-19 (2  ￿  10 calls/well) in 96-well flat-bottomed plates (Falcon Labware) in a total volume of 200/~1, as indicated. 
Anti-BT, anti-HLA-DR, and anti-CD4 mAbs were added at 5/zg/ml. Cultures were incubated at 37~  with 5% CO2 in a humidified atmosphere 
for 6 d. Cultures were hbeled for the final 4 h with 1 #Ci/well  [3H]thymidine  (New Enghnd Nuclear, Boston, MA), were harvested using a 96-well 
plate harvester (LKB, Pharmacia, Piscataway, NJ), and radioactivity was measured using a ~ scintilhtion counter. Small, resting PBL T cells isolated 
by PercoU gradient centrifugation are unable to respond to anti-CD3 stimuhition in the absence of appropriate accessory  cells (13). The irradiated 
AW27-19 B7  + CD4 + T cells used as stimulators were >99%  CD3 § and did not contain any detectable contaminating B cells or monocytes in 
the population, as determined using flow cytometric analysis. For determination of IFN-q~ secretion, supernatants from MLR cultures were harvested 
after 48 h, and IFN-3, was measured by an ELISA using anti-IFNw-spedfic mAb (30). Data are expressed as IFN-3' (pg/ml)  secreted per 106 cells 
(lower limit of detection was 50 pg/ml). 
* Numbers in parentheses represent percent inhibition, relative to control values. 
antigens in an antigen-specific,  MHC-restricted  fashion, al- 
though the antigen-processing capacity of T  and NK cells 
are limited relative to macrophages  (28, 29). Since activated 
T  cells can coexpress  both CD28 and its counter-receptor, 
B7, this suggests the possibility that activated  T  calls may 
be capable of autocrine costimulation via the CD28 activa- 
tion pathway under certain  circumstances. 
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Note added inproof Sansom and Hall (31) have also recently observed expression of B7 on activated T ceLls. 
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